In September 2022, we hosted our International Research Workshop virtually, and in conjunction with our Together We Will Virtual Weekend. Over ~160 physicians and researchers signed up for the 2022 Research Workshop, expanding our worldwide participation to ~100 institutions from 30 countries.
Agenda
Introduction
Jeanne Whiting
Executive Director and Co-Founder, The DTRF
Welcome
Ben Alman, MD
Department Chair, Orthopedic Surgery, Duke University
Investigating EZH2 as a druggable mediator of immune cell exclusion in desmoid tumors.
Kris Vleminckx, PhD
Professor of Developmental Biology, Ghent University
The proteomic landscape of desmoid tumours.
Paul Huang, PhD
Head, Molecular and Systems Oncology Laboratory, Division of Molecular Pathology, The Institute of Cancer Research
Targeting hexosamine biosynthesis pathway for the treatment of desmoid tumors.
Joanna Przybyl, PhD
Assistant Professor, Department of Surgery, McGill University & Principal Investigator, Cancer Research Program, Research Institute at The McGill University Health Centre
Progress Towards a Desmoid Tumor Dependency Map.
Jesse Boehm, PhD
Chief Science Officer, Break Through Cancer; Principal Investigator, MIT, affiliated researcher, Broad Institute
Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis.
Gerlinde Wernig, MD
Assistant Professor, Department of Pathology, Stanford University School of Medicine and Cristabelle Madona De Souza, PhD, Postdoctoral Fellow, Department of Pathology, Stanford University
Jason Ortwerth
Desmoid Tumor Patient Advocate
Prospective observational study of active surveillance in primary desmoid fibromatosis.
Alessandro Gronchi, MD
Chair of Sarcoma Service – Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute)
MRI T2 mapping in desmoid tumors: a quantitative imaging biomarker of tumor response with high inter-reader reliability.
Ty Subhawong, MD
Associate Professor of Clinical Radiology, and Vice-Chair for Research, Department of Radiology, The University of Miami Miller School of Medicine
Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1.
Aimee Crago, MD, PhD, FACS
Associate Attending Surgeon, Memorial Hospital, Memorial Sloan Kettering Cancer Center/ Associate Professor, Weill Cornell Medical Center
Comparative Effectiveness of Systemic Treatments in Desmoid Tumors.
Philippos Costa, MD
Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors.
Benjamin Wilke, MD
Assistant Professor and Senior Associate Consultant in the Department of Orthopedic Surgery at Mayo Clinic
Nirogacestat for the Treatment of Desmoid Tumors.
Ravin Ratan, MD
Associate Professor, Sarcoma, MD Anderson Cancer Center
Initial Results of Phase ⅔ Trial of AL102 for Treatment of Desmoid Tumors (DT).
Rashmi Chugh, MD
Professor of Internal Medicine in the Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Rogel Comprehensive Cancer Center
TUPELO TRIAL: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of REC4881 in Subjects with Familial Adenomatous Polyposis (FAP) Study Design.
Diana Shuster, PhD
Senior Director of Clinical Pharmacology, Recursion Pharmaceuticals
Closing
Jeanne Whiting
Executive Director and Co-Founder, The DTRF and Benjamin Alman, MD, Professor & Chair, Orthopaedic Surgery, Duke University
